Givastomig

吉伐苏米单抗

Report date: 2026/03/06 20:02:51

Base Information

Drug NameGivastomig
Drug Alias NameTJ-CD4BABL-111TJ-CLDN4BTJ-033721TJ-CD4B/ABL111
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionTumor necrosis factor receptor superfamily member 9 inhibitorsAnti-CLDN18
TargetsClaudin-18 splice variant 2Tumor necrosis factor receptor superfamily member 9
Therapy Area/IndicationsEsophageal adenocarcinomaGastroesophageal Junction NeoplasmsSolid tumours +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSouth KoreaMainland China +[4] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesI-Mab Biopharma Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesAbl Bio IncI-Mab Biopharma Us LtdI-Mab Biopharma Co Ltd
Inactive CompaniesN/A
Active IndicationsEsophageal adenocarcinomaGastroesophageal Junction NeoplasmsSolid tumours +[8] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A